Optimality of Mutation and Selection in Germinal Centers

Jingshan Zhang, Eugene I. Shakhnovich*

Department of Chemistry and Chemical Biology, Harvard University, Cambridge, Massachusetts, United States of America

Abstract

The population dynamics theory of B cells in a typical germinal center could play an important role in revealing how affinity maturation is achieved. However, the existing models encountered some conflicts with experiments. To resolve these conflicts, we present a coarse-grained model to calculate the B cell population development in affinity maturation, which allows a comprehensive analysis of its parameter space to look for optimal values of mutation rate, selection strength, and initial antibody-antigen binding level that maximize the affinity improvement. With these optimized parameters, the model is compatible with the experimental observations such as the ~100-fold affinity improvements, the number of mutations, the hypermutation rate, and the “all or none” phenomenon. Moreover, we study the reasons behind the optimal parameters. The optimal mutation rate, in agreement with the hypermutation rate in vivo, results from a tradeoff between accumulating enough beneficial mutations and avoiding too many deleterious or lethal mutations. The optimal selection strength evolves as a balance between the need for affinity improvement and the requirement to pass the population bottleneck. These findings point to the conclusion that germinal centers have been optimized by evolution to generate strong affinity antibodies effectively and rapidly. In addition, we study the enhancement of affinity improvement due to B cell migration between germinal centers. These results could enhance our understanding of the functions of germinal centers.

Introduction

As one of the adaptive immune responses [1,2,3,4], Affinity Maturation (AM) is the procedure in germinal centers (GC) to develop Immunoglobulins (Ig), i.e., antibodies, with increased affinities to a new antigen. Understanding the basic functional and physical principles of GC kinetics is not only important in medical science, but also contributes to the fundamental understanding of molecular evolution [5]. Mathematical models by Perelson and coworkers [6,7] made an important effort to describe the B cell population in a typical GC as a result of dynamic interactions between mutation and selection. This effort, complementary to the studies using Ig sequence data [e.g. 8], is very important in revealing the functions of germinal centers. However, there are still two puzzles in the models. First, the experimentally observed somatic hypermutation [9] rate was viewed as [6] so high that even B cells expressing antibodies with improved affinities are easily spoiled by the majority of deleterious mutations. To resolve the conflict, it is proposed [6,10] that the mutation could be switched off periodically. Second, even if the mutation rate is tuned periodically, the calculated affinity improvement (up to 15-fold) is still not comparable with the observed improvements (~100-fold [11,12,13,14]). Deem and coworkers [15] used a version of random energy model to describe the alternative rounds of mutations and selection, assuming 100-fold affinity improvement. While this is helpful in sketching the AM procedure, it is interesting to explore the values of selection strength and antigen concentration that lead to the sufficient affinity improvement consistent with experiments. Third, a further analysis indicated that the models did not reproduce the “all or none” phenomenon [8], i.e., the fraction of B cells with strong affinity Ig is more likely to be high or low, but less likely to be intermediate.

Since most of the parameters in the models are estimated from experiments with considerable uncertainties, it is possible to reconcile the discrepancies by revising the parameter values. However, the number of parameters in Perelson’s models is not small, and it is unclear how to find the best parameter values. We notice that the affinity dependent selection results from antigen binding kinetics, salvation, and recirculation of B cells. If we replace these steps by a phenomenological linear function of affinity to represent the selection, the calculations will be significantly simplified, and it will be possible to explore the parameter space and look for the optimal design. We hypothesize that AM has been optimized in evolution, and expect the B cell population dynamics with these optimized parameters to reproduce realistic AM.

Methods

The model

Each GC is believed to start from a few precursor B cells [16]. These precursor B cells first replicate at the perimeter of follicles...
Author Summary

The antibodies in our immune system could efficiently improve their abilities in recognizing new antigens. This is done with the help of proliferation, mutation and selection of B cells which carry antibodies, but we have difficulties in developing a quantitative description of this adaptation process which is consistent with the various aspects of experimental observations. Based on the knowledge from experiments, here we present a theoretical model to calculate the numbers of B cells with different antigen recognizing abilities all the time, and look for the best possible design that improves the antigen recognizing ability most efficiently. We find that the best possible design is consistent with the experimental observations, pointing to the conclusion that the immune system has been optimized in evolution. We then study the trade-offs leading to the optimization of the design. The results will not only improve our understanding of the functions in immune system, but also reveal the design principles behind the details. In addition, the study enhances our understanding of the population dynamics in evolution.

[17], and the number of B cells in a GC reaches thousands when mutations and affinity dependent selections are turned on [7,18,19,20,21]. Our model is constructed as follows:

First, the model describes the stage with mutation and selection, where the total number of germline (initial) B cells in the hundreds of GC in a spleen is \( \sim 10^6 \). B cells replicate at 3–4 divisions/day [22,23,24]. To be specific we use 4 divisions/day in our calculations, corresponding to exponential birth rate \( r = 4n^2 = 2.8 \text{ day}^{-1} \). Upon every division about one of the two daughter cells are mutated [9], so we find the total mutation rate \( m_{\text{total}} \approx 2.8 \text{ day}^{-1} \) from \( \exp(-m_{\text{total}}0.25) \approx 1 - 1/2 \), although in the calculation below we will explore different values of \( m_{\text{total}} \) to search for the optimal design. It is estimated [25,26] that about 50% mutations are silent, 30% are lethal, and the rest 20% are the affinity-affecting mutations. The lethal mutation rate 0.3\( m_{\text{total}} \) is an effective death rate. After taking care of the lethal mutations and neglecting silent mutations, we concentrate on the affinity-affecting mutations. Affinity can be described by the Ig-antigen binding free energy \( X \). Define \( \Delta X \) as the change of \( X \) upon a point mutation. The distribution \( W(\Delta X) \) of affinity change \( \Delta X \) upon such single point mutations (Figure 1) is estimated from the protein interaction (PINT) database [27] (see Text S1 for details). Note that only 4.9% of affinity-affecting mutations (equivalent to 1% of all mutations) improve the affinity, i.e. \( \Delta X < 0 \). We assume \( W(\Delta X) \) is independent of the affinity \( X \) before the mutation. In support of this assumption, we found no significant correlation between \( \Delta X \) and \( X \) in the data of PINT database (see Figure S1). Although it might become hard to further improve affinity when it is already very high, our model only requires this assumption to be valid in a range 2–4 kcal/mol from the germline affinity.

Second, selection is considered on the basis of the recent two-photon spectroscopic studies which indicate B cells undergo photon spectroscopic studies which indicate B cells undergo...
and the affinity-affecting mutations are characterized by $W(\Delta X)$ in Figure 1, where $\Delta X = X - X'$ is the affinity change.

We can solve the mean field equation (2) when Eq. (1) can be simplified as Eq. (1a), i.e., the effective growth rate (i.e. replication rate minus death rate) depends linearly on the binding free energy in the whole range. Then we rewrite growth rate $B(X) = b_0 - bX$ where $b_0 \equiv r - 0.3m_{\text{total}} + bX_0$. We introduce a Fourier transform of the population:

$$N(t, \omega) = \frac{1}{2\pi} \int N(X, t)e^{-i\omega X} dX$$ (3)

Then in terms of the Fourier transform population, Eq. (2) looks simple:

$$\frac{\partial N(\omega, t)}{\partial t} = b_0 N(\omega, t) - i\frac{\partial N(\omega, t)}{\partial \omega} + m[2\pi W(\omega) - 1]N(\omega, t)$$ (4)

where

$$W(\omega) = \frac{1}{2\pi} \int e^{-i\omega \Delta X} W(\Delta X) d\Delta X$$

Now denoting

$$Q = \ln N(\omega, t)$$ (5)

we get

$$\frac{\partial Q}{\partial t} + i\frac{\partial Q}{\partial \omega} = b_0 + m[2\pi W(\omega) - 1]$$ (6)

We seek solution of this equation in the form:

$$Q = R(\omega - ibt) + S(\omega)$$ (7)

and get for $S$:

$$ib\frac{\partial S}{\partial \omega} = b_0 + m(W(\omega) - 1)$$ (8)

or

$$S = b_0 - m - \frac{ib}{b} - \frac{2\pi m}{b} \int_{-\infty}^{\omega} W(\omega')d\omega' + C$$ (9)

where $C$ is constant to be determined.

The function $R$ and the constant $C$ are determined from the initial condition at $t = 0$, i.e., the germline distribution of affinities. The general results applicable for different initial conditions will be addressed shortly; for the moment we adopt a most common initial condition, Gaussian distribution

$$N(X, t = 0) = \frac{N_0}{\sqrt{2\pi}\Sigma^2} \exp \left[ -\frac{(X - X_0)^2}{2\Sigma^2} \right]$$ (10)

of affinity, or in Fourier space:

$$N(\omega, 0) = \frac{N_0}{2\pi} \exp \left[ -\frac{1}{2}\Sigma^2 \omega^2 - i\omega X_0 \right]$$

Now the function $R$ and constant $C$ can be easily determined from the relation:

$$N(\omega, 0) = e^{Q(\omega, 0)}$$

which immediately gives us $C = \ln (N_0/2\pi)$ and final result for $R$ and $Q$:

$$R(\omega) = -\frac{1}{2} \Sigma^2 \omega^2 - i\omega X_0 + ib_0 - m - \frac{2\pi m}{b} \int_{-\infty}^{\omega} W(\omega')d\omega'$$

Plugging these results to Eq. (7), we obtain the solution

$$Q(\omega, t) = -\frac{1}{2} \Sigma^2 \omega^2 - i\omega X_0 + \Sigma^2 bt + t(b_0 - m - bX_0)$$

and accordingly

$$N(\omega, t) = \frac{N_0}{2\pi} \exp \left[ -\frac{1}{2} \Sigma^2 \omega^2 - i\omega (X_0 - \Sigma^2 bt) + t(b_0 - m - bX_0) \right]$$

$$+ \frac{1}{2} b^2 \Sigma^2 t^2 + i\frac{2\pi m}{b} \int_{-\infty}^{\omega} W(\omega')d\omega'$$ (11)

Notice

$$\exp \left[ \frac{a + ibt}{b} \right] = \exp \left[ \frac{1}{b} \int_{-\infty}^{\omega} W(\omega')d\omega' \right]$$

we can define a Fourier transform pair $f(\Delta X, t) = \frac{2\pi m W(\Delta X)}{b}$

$$e^{-\frac{b\Delta X}{2}} - 1$$

and

$$F(\omega, t) = \exp \left[ \frac{m}{b} \int_{-\infty}^{\omega} W(\Delta X)d\Delta X \right]$$

we can define a Fourier transform pair $f(\Delta X, t) = \frac{2\pi m W(\Delta X)}{b}$

$$e^{-\frac{b\Delta X}{2}} - 1$$

and

$$G(\omega, t) = \frac{N_0}{2\pi} \exp \left[ -\frac{1}{2} \Sigma^2 \omega^2 - i\omega (X_0 - \Sigma^2 bt) + t(b_0 - m - bX_0) + \frac{1}{2} b^2 \Sigma^2 t^2 \right]$$

then Eq. (11) becomes

$$N(\omega, t) = G(\omega, t) \exp \left[ F(\omega, t) \right]$$

$$= G(\omega, t) \left[ 1 + F(\omega, t) + \frac{1}{2} b^2 F^2(\omega, t) + \frac{1}{3!} b^3 F^3(\omega, t) + \cdots \right]$$ (12)
With help of the Fourier convolution theorem

$$\frac{1}{2\pi} \int dX e^{-\omega \Delta X} \left( \int f(X - X') g(X') dX' \right) = 2\pi F(\omega) G(\omega),$$

we obtain the final exact solution for the selection-diffusion equation (2)

$$N(X, t) = g(X, t) + \frac{1}{2\pi} \int g(X') f(X - X') dX' + \frac{1}{2\pi} \int g(X') (X'' - X') dX' dX'' + \ldots$$

$$= g(X, t) + \frac{1}{2\pi} \int g(X - \Delta X) f(\Delta X) d\Delta X$$

$$= \frac{1}{2\pi (2\pi)^2} \int g(X - \Delta X_1 - \Delta X_2) f(\Delta X_1) f(\Delta X_2) d\Delta X_1 d\Delta X_2 + \ldots$$

$$= \tilde{N}(X) e^{-mt} + \sum_{j=1}^{\infty} \frac{1}{j!} \left( \frac{m}{\Delta X} \right)^j \int d\Delta X_1 \frac{W(\Delta X_1)}{\Delta X_1} (e^{-b\Delta X_1} - 1) \ldots$$

$$\ldots \int d\Delta X_j \frac{W(\Delta X_j)}{\Delta X_j} (e^{-b\Delta X_j} - 1) \tilde{N}(X - \Delta X_1 - \ldots - \Delta X_j, t) e^{-mt}$$

where $\tilde{N}(X, t) = g(X, t) e^{-mt} = N(X, t=0) \exp \left( \frac{\Delta X}{\Delta X} t \right)$ is the population profile in the limit of $m = 0$. Due to the linearity of Eq. (2), Eq. (13) applies generally to any initial condition. The total population is

$$N(t) = \int N(X, t) dX = \int \tilde{N}(X, t) e^{-i\omega X} dX = 2\pi N(\omega = 0, t)$$

$$= N_0 \exp \left( b_0 - b X_{av} \right) + \frac{1}{2} \Sigma^2 \tau^2$$

$$\cdot \exp \left[ -mt - \frac{m}{\Delta X} \int \frac{e^{\Delta X} - 1}{\Delta X} W(\Delta X) d\Delta X \right]$$

$$= \tilde{N}(t) \exp \left[ -mt - \frac{m}{\Delta X} \int \frac{e^{\Delta X} - 1}{\Delta X} W(\Delta X) d\Delta X \right]$$

The effects of mutations are in the exponent containing $m$, and this exponent applies universally to initial conditions other than Eq. (10). At long enough time beneficial mutations $\Delta X < 0$ contribute a growing term $\frac{m}{\Delta X} e^{\Delta X} W(\Delta X) d\Delta X$ because $e^{-b\Delta X} \approx 1$; while the deleterious mutations $\Delta X > 0$ mainly contribute to the population reduction term $-mt$ because $e^{-b\Delta X} \ll 1$.

**Intuitive derivation**

An intuitive derivation of (14) helps us understand its physical meaning. For convenience we use discrete values of $\Delta X_i = -ih$ in Figure 1, and write the total mutation rate as a sum of individual mutation rates, $m = \sum m_i$ where $m_i$ is the rate of mutation that change affinity by $\Delta X_i = -ih$. Then Eq. (14) becomes:

$$N(t) = \tilde{N}(t) \prod_j \exp \left[ -m_i d_t + \frac{m_i}{b_i h_i} (e^{b_i h_i} - 1) \right].$$

Note that beneficial mutations ($j > 0$) contribute $-m_j t + \frac{m_j}{b_j h_j} (e^{b_j h_j} - 1) \ln N(t)$. Therefore in the long time limit the beneficial mutations with leads to a super-exponential population growth $N(t) \sim \exp \left[ \exp (t) \right]$, in comparison to the exponential population growth without mutation. As the high affinity edge moves toward stronger affinity, the subpopulation at the edge grows faster, and the speed of edge movement becomes faster.

The effects of different mutations in Eq. (15) can be factored out, because a) the rate $m_i$ for a mutation of $\Delta X_i = -ih$ to emerge is independent of the affinity distribution $N(X, t)$, and b) the contribution of a series of mutations $\{\Delta X_i\}$ occurring at $\{t_i\}$ to the subpopulation size at a later time $t$ is $\prod_i \exp \left( b_i \Delta X_i (t - t_i) \right)$, a product of individual mutation factors. Therefore, to understand Eq. (14), we can focus on effect of only one mutation type with affinity change $\Delta X_i = -ih$ and individual mutation rate $m_i$.

First, in the limit of $b \to 0$ in Eq. (1), the benefit of mutations is turned off, and the average number of mutations $B$ cells experience in the interval $t$ is $m_i t$, and the probability to experience $j$ mutations is a standard Poisson distribution $P_j(t) = \exp \left( -m_i t \right) = \frac{m_i t}{j!} \exp (b_i h_i) - 1$, It is straightforward to verify

$$N(t) = \tilde{N}(t) \sum_j P_j(t) = \tilde{N}(t) \exp \left( -m_i t \right) \sum_j \frac{1}{j!} \left( \frac{m_i}{b_i h_i} (e^{b_i h_i} - 1) \right)^j$$

$$= \tilde{N}(t) \exp \left( \frac{m_i}{b_i h_i} (e^{b_i h_i} - 1) - m_i t \right)$$

This matches Eq. (15) and more generally Eq. (14). From Eq. (18), the subpopulation of B-cells which undergo $j$ mutations is

$$N_j(t) = \tilde{N}(t) P_j(t) = \tilde{N}(t) \exp \left( -m_i t \right) \frac{1}{j!} \left( \frac{m_i}{b_i h_i} (e^{b_i h_i} - 1) \right)^j,$$

with affinity $b_i h_i$ stronger than the subpopulation without mutations. If the affinity of the initial population are all the same $X_m$, then $N_j(t)$ is the subpopulation with affinity $X_m + j b_i h_i$. For $i > 0$, the peak of subpopulation, i.e., largest subpopulation, is at

$$j_{\text{peak}} = \frac{m_i}{b_i h_i} (e^{b_i h_i} - 1) \approx \frac{m_i}{b_i h_i} e^{b_i h_i},$$

i.e., the peak moves exponentially fast in the long time limit.

From Eq. (19) a subpopulation with $j$ mutations grows for two reasons, (a) fed from subpopulations with $j-1$ mutations and (b) self-replication. At short enough time, $b_i h_i \ll 1$, the subpopulation grows $d N_j(t)/dt \approx N_j(t) m_i$ mainly for the former reason; and for large enough time, $b_i h_i \gg 1$, the subpopulation growth $d N_j(t)/dt \approx N_j(t) b_i h_i$ is mainly contributed by the latter reason. Therefore, the artifact of self-replication is insignificant when time step is much shorter than the characteristic time duration $1/b_i h_i$. 
Numerical calculation for finite population

An artifact in the above derivation is that it allows arbitrarily small \(N(X, t)\), and a small subpopulation \(N(X, t)\) within a bin of strong affinity \(x\) can self-replicate rapidly. However, the B cell numbers in GCs are non-negative integers, therefore the expected number of B cells within a bin with \(N(X, t)\) should be zero, and cannot become the seed of a rapid growth. So the above derivations actually describe the population dynamics in the limit of infinitely large population size. It does not take into account the fact [31] that the B cell population size in a GC is no more than \(10^4\).

To correct this artifact and calculate the B cell population dynamics numerically for various finite initial population sizes including the discreteness effect [7,30], we do not allow small subpopulation \(N(X, t)<1\) in an affinity bin to self-replicate in our numerical calculation. Instead, it only represents an accumulative probability for the subpopulation in the bin to emerge. Our calculation is done using discrete time steps. From Eq. (15), the subpopulation which go through \(\delta j\) mutations \(X = -\delta h\) between time \(t\) and \(t+\Delta t\) is

\[
N_{j_1,j_2,...,j_p}(X, t+\Delta t) = N'(X) \prod_{j_1=0,1,...}^{j_1} \prod_{j_2=0,1,...}^{j_2} \cdots \sum_{j_p=0,1,...}^{j_p} N_{j_1,j_2,...,j_p}(X, t+\Delta t)
\]

where \(N_{j_1,j_2,...,j_p}(X, t+\Delta t)\) is the population distribution excluding the bins with less than one B cells. The population distribution after a time step is

\[
N(X, t+\Delta t) = N(X, t) - N'(X, t) + \sum_{j_1=0,1,...}^{j_1} \sum_{j_2=0,1,...}^{j_2} \cdots \sum_{j_p=0,1,...}^{j_p} N_{j_1,j_2,...,j_p}(X, t+\Delta t)
\]

The time step \(\Delta t\) is set to 0.01/\(bh\), much smaller the characteristic time duration 1/\(bh\), such that the growth of subpopulations with relatively strong affinities is dominated by mutation influx rather than self replication. We include multiple mutations in one time step. This calculation is rapid to perform even for large population sizes, and allows us to explore the parameter space.

The population dynamics here differs from the case of constant population size [30,32,33,34,35]. Indeed, the “neutral” affinity \(X^*\), which corresponds to zero population growth rate \(B(X^*) = 0\), does not change over time. This makes it straightforward to find solution Eq. (13–14). Random drift beyond mean field calculations is important in the case of constant population size [32,33,34,35], especially if population growth rate is small, \(s\ll 1\), at the high affinity edge, because birth rate and death rate are very close. However, the growth rate in units of proliferation rate in our model \(B(X)/r\), which is similar to \(s\), differs by about 1/8 between two nearest affinity bins for a typical value \(b=0.7/\text{day}/\text{kcal/mol}\), so \(s\) at high affinity edge typically is not close to zero. Hence the effect of random drift is not overly significant in our model, although a future treatment including stochastic calculation will give more precise results.

Results

We calculate the total population size of B cells \(N(t)\) for various initial population sizes numerically (dotted lines in Figure 2). The total number of B cells first decreases because the initial affinity is weaker than the neutral affinity \(K_n\). The average affinity is improved continuously (see Figure S2) rather than abruptly, in agreement with experiments [28]. Once the average affinity reaches \(K_n\), the population begins to increase. The picture of decrease and increase of the B cell population was observed experimentally [36] and theoretically [7], although the experimental data on GC temporal development [36] is too limited to verify the model. The lowest total population corresponds to the neutral affinity \(K_n\); and we call it the population bottleneck, because it is the most challenging moment for the population to survive. The analytical result Eq. (14) (solid line) can describe the population size at the decreasing stage. A smaller initial population leads to a slower growth after the bottleneck (yellow). For a small enough initial population (red), the B cell population is extinct when approaching the bottleneck, and cannot recover thereafter. Therefore, the initial population size should be large enough to ensure some B cells can survive through the population bottleneck. Similarly, for a given initial population size, a weaker initial binding leads to a deeper bottleneck, and takes a longer time to recover. If the initial binding is too weak, the bottleneck will be too deep, and the population will go extinct.

The initial population is set to \(10^6\) B cells in realistic calculations to include the existence of hundreds of GCs in a spleen [37] and the peak number of thousands of B cells per GC [38]. Different GCs in a spleen might not be perfectly synchronized [39]. If the B cell production rate in a spleen is limited by supply of resources, we conjecture the time that GCs start mutation and selection might vary between day 3 and day 8 or later, so that the population peaks of GCs is smeared. This agrees with the observation [40] that the total population at any moment does not exceed \(2.5 \times 10^3\) B cells. The population bottleneck within a GC might also be smeared by the continued immigration of B cells from nonfollicular sites [20,41], making the bottleneck less pronounced or harder to observe directly. If all the B cells in a GC die away, the antigens are not exhausted, and it is proposed that more B cells immigrate to the GC [39], probably from GCs which have passed the bottleneck and have many B cells, although the current experiments cannot determine whether there is migration between GCs [39]. The calculations below are first performed with \(10^6\) initial B cells, which is valid in the limit of fast migration between GCs in a spleen. In this case, the few GCs...
which by chance pass the bottleneck earlier than others may make significant contributions to the affinity improvement of the whole spleen. Then we study the case in the opposite limit, i.e. the affinity improvement of a typical GC with 3000 initial B cells, assuming no B cell migration between GCs. By comparing these two cases we will quantify the contribution of migration to affinity improvement.

We explore the parameter space to look for the optimum design of GCs that maximizes the affinity improvement (Figure 3) in the limit of fast B cell migration between GCs ($10^8$ initial B cells). AM terminates probably due to exhaustion of available antigens [42,43] or emigration of B cells [42,44], and the termination could be described to occur after a certain time scale, or when the B cell population size is big enough—probably comparable to its original size. So if the population size recovers the initial value in less than 14 days, we assume that the total affinity stops to change in the situation with very few cells at day 14 should not be regarded as efficient improvement. The improvement of affinity in Figure 3a is calculated when the B cell population size recovers the initial value after going through the bottleneck. If the initial binding of antibodies and antigens is $X_0 = X^* + 1\text{kcal/mol}$ or $K_0/K^*_a = \exp(-1\text{kcal/mol}/kT) = 0.18$, and selection strength $b = 0.7/\text{day}\times(\text{kcal/mol})$ (see Figure S3 and S4). This result agrees with several experimental observations. First, the affinity improvement agrees with the observation of ~100-fold [11,12,13,14] improvement. Second, the theoretically optimal value to provide maximal affinity improvement agrees with the observed in vivo somatic hypermutation rate [9]. Third, the improvement of affinity corresponds to $\ln(450/kT) \approx 3.6\text{kcal/mol}$ of free energy improvement. Combining with the typical affinity improvement $Y \approx 0.4\text{kcal/mol}$ of an affinity improving mutation, we can estimate that a final B cell contains 3.6/0.4 = 9 mutations in their V regions of Ig genes, in agreement with the observed ~9 mutations per Ig gene [9,45,46,47,48]. From the definition $b = 1/(kT\tau)$, the optimal selection strength $b = 0.7/\text{day}/(\text{kcal/mol})$ corresponds to an optimal time of a recycling round $\tau = 1/(kTb) \approx 2.4\text{day}$, compatible with the earlier model [7].

Figure 3b helps to reveal the design principles of GCs, where the affinity improvement is calculated when the B cell population size recovers the initial value after going through the bottleneck, no matter how long it takes. In general, the affinity improvement is not effective for too strong initial bindings, which results in shallow or no bottlenecks and rapid population recoveries, hastily terminating the AM before accumulating adequate improvements. As the initial binding becomes weaker, the population bottleneck is deeper, and the affinity improvement is more effective, but takes a longer time. The improvement shown in Figure 3b could even exceed 1000-fold for a weak initial binding $X_0 = X^* + 1.5\text{kcal/mol}$, although such improvements take much longer than 14 days and would be interrupted in the calculation with fixed AM time as shown in Figure 3a. If the initial binding becomes even weaker, the population bottleneck is so deep that the whole population goes extinct and no longer recovers (grey scales in Figure 3b obtained numerically). Therefore, for a given mutation rate, the most effective affinity improvement occurs when initial binding level is near the critical value (red in Figure 3b), where the population can barely survive through the population bottleneck, i.e. only a few GCs can survive. A somewhat stronger initial binding improves affinities less effectively but takes a shorter time for the AM to finish, and faster AM is advantageous. Taking all these into consideration, in the optimal design of GCs, the most commonly appeared initial bindings should be adjusted to be somewhat stronger than the critical value, so that affinities are improved effectively, timely, and safely. This picture agrees with the observed dependence of B cell fate on initial antibody-antigen binding level or antigen density [49–50], where too strong initial bindings (beyond $K_a^*$ in our model) do not lead to GC formation, moderate initial bindings (e.g. $X_0 = X^* + 0.5\text{kcal/mol}$ in our model) result in GC response which finishes quickly, while weaker initial affinities (e.g. $X_0 = X^* + 1\text{kcal/mol}$ in our model) result in tempered GCs. To achieve the optimal design, the $K_a^*$ values might have been adjusted in evolution by tuning the antigen density or modulating the diversity of the germline pool achieved through somatic recombination. When mutation rate is so high that 80% or more daughter cells are mutated, the lethal mutations preclude sustainable replications of B cells, i.e., the population growth rate in Eq. (1) becomes negative for any affinity. This lethal mutagenesis region is shown in black in Figure 3b.

B cell migration between GCs could be beneficial to the AM, as indicated by the calculated affinity improvement of a typical GC.
with 3000 initial B cells in the limit of no migration (Figure 4). A stronger initial binding \( X_0 = X^* + 0.5 \text{kcal/mol} \) is needed to ensure a typical GC to survive through the bottleneck; and the optimal affinity improvement becomes 70-fold for the GC, still consistent with the experimental value (of the order \( \sim 100\)-fold [11,12,13,14]). This is achieved in 16 days, only slightly longer than two weeks, therefore separate diagrams like in Figure 3a and 3b is not necessary. The maximal improvement in this case is \( \sim 6-7 \) times lower than the result in the limit of fast migration, where a factor of \( \sim 3 \) comes from the change in initial binding level, and a factor of \( \sim 2 \) comes from the difference between the average of all GCs and the “typical” or median individual GC. In other words, fast B cell migration between GCs could enhance the affinity improvement by a factor of \( \sim 6-7 \) in our model.

Our model is consistent with the “all or none [8]” phenomenon observed in experiments [20,51,52], i.e., the fraction of strong affinity cells in a GC is most likely either very high or very low, while the strong affinity B cells are characterized by a certain key mutation [51,52] or a unique piece of Ig gene sequence [20]. Presumably the GCs dominated by strong affinity mutants have gone through the population bottleneck, and this phenomenon is the most pronounced in the case without B cell migration between GCs. Indeed, it is possible for different individual GCs to fall into two categories according to whether they have passed the population bottleneck, and the choice of category for a GC depends on both the initial binding level and stochastic effect. Moreover, if many GCs in a spleen start from the same initial condition but each has a random starting time, then the fractions of strong affinity B cells in the GCs at a given moment is expected to be distributed as in Figure 5, where affinities beyond \( K_a^* \) are defined as strong. Figure 5 is obtained as follows. During the development of a typical GC (Figure 2 and S2), we can track the fraction \( F(t) \) of strong affinity B cells in the GC all the time. Observing the whole ensemble of GCs at a given moment is equivalent to observing a single GC at many arbitrary moments. Therefore, we transform \( F(t) \) into \( t(F) \), and the distribution is \( P(F) \sim dt(F)/dF \) up to a normalization factor. As we see in Figure 5, the probabilities to observe high or low fraction values are significantly larger than that of intermediate fraction values. Therefore, our model is consistent with the “all or none” phenomenon. If B cell diffusions between GCs exist, this phenomenon is somewhat smeared.

**Discussion**

Since the calculated AM procedure at the optimal set of parameters is consistent with the various aspects of experimental observations, it is likely that evolution has chosen the optimal design. Moreover, exploration of the parameter space, illustrated in Figure 3, 4, S3 and S4, helps us sketch some general design principles of the GCs. First, for the affinity to be improved most effectively, the B cell number should first decrease to reach a population bottleneck and then increase. A weaker initial binding leads to a higher affinity improvement, but a too weak initial binding makes it impossible for the B cell population to go through the bottleneck and recover. Second, the seemingly high mutation rate is actually set to optimize the success rate of AM. On one hand, the optimal mutation rate, in agreement with somatic hypermutation \textit{in vivo}, is quite high because the improvement of affinity comes only from mutations. On the other hand, if the mutation rate gets even higher, the large number of lethal mutations will spoil the cell replications. Third, we expect that the selection strength \( b \) is the optimal value \( b = 0.7/\text{day}/(\text{kcal/mol}) \), which sets an important guide to future simulations of GCs.

We obtained mutation effects \( W(\Delta X) \) from the PINT database which presents the data on interactions between all kinds of proteins [27] because we do not have adequate real data of affinity change upon mutations of Ig. The existing analysis of Ig sequence data in the immune response of PhOx and NP [8] is consistent with the distribution obtained from the PINT database. Indeed, 3.2% (for PhOx) or 1.0% (for NP) of the affinity affecting mutations could improve affinity strongly (10-fold), while in our model 4.9% improves affinity and 1.4% improves affinity strongly (5-fold).

The random energy NK model of Deem and coworkers [15] included rugged landscapes without special assumptions on the Ig mutagenesis. On the other hand, using an approximate distribution

**Figure 4.** The improvement of affinity for an isolated GC, i.e., in the limit of no B cell migration between GCs. The improvement of AM (sum of \( K_a \)) is shown in the same color code as in Figure 3a, assuming AM is terminated when the population recovers the initial size (3000 B cells). The optimal improvement of affinity occurs when about 60% daughter cells are mutated at divisions, and takes 16 days. The grey scale shows the probability for a GC to survive through the bottleneck. doi:10.1371/journal.pcbi.1000800.g004

**Figure 5.** The distribution of \( F \), fraction of strong affinity B cells, for many GCs which follow similar development patterns but each starts from a random time, is consistent with the “all or none” phenomenon. Every GC has initial binding level \( X_0 = X^* + 0.5 \text{kcal/mol} \), 50% mutated daughter cells, and selection strength \( b = 0.7/\text{day}/(\text{kcal/mol}) \). The calculation is terminated when the population in the GC recovers the initial size (3000 B cells), and \( F \) reaches 85% at the termination moment. doi:10.1371/journal.pcbi.1000800.g005
of affinity improvements upon point mutations, we explored the values of selection strength, initial binding level and mutation rate that maximize the affinity improvement. Similarly to our work, the Oprea-Perelson (OP) model [7] explores the parameter values to optimize AM. What are the major differences between the OP model and our model? First, the affinity improvement we achieve is higher than in the OP model, which resolves the discrepancy between theory and experiment. If we examine the OP model in our framework, the reason that the OP model did not achieve higher improvements might be that it used a smaller selection strength b than the optimal value. Indeed, the choice to enter a recycle in the OP model is stochastic, so the chance for weak affinity B cells to survive is enhanced by choosing not to enter a cycle and therefore avoiding selection. A larger selection strength b brings a high risk of AM failure, but provides a higher affinity improvement, and this can be achieved if all B cells experience similar number of recycles rounds. The low optimal value of mutation rate in the earlier model might result from the small selection strength. Second, the major simplification we make is to use Eq. (1) to replace the binding kinetics between Ig and antigens, salvation, recycling, the distinction between different B cell phenotypes such as centroblasts and centrocytes, and the separation of dark and light zones, which were considered in details in earlier theoretical studies [7,8,42,43,44,53,54]. We assume that competition for antigen and T-cell help effectively results in the dependence of death rate of B centrocytes, and the separation of dark and light zones, which were considered in earlier theoretical studies [7,8,42,43,44,53,54]. We assume that competition for antigen and T-cell help effectively results in the dependence of death rate of B cells on their affinity to an antigen, and we provided an argument that such dependence should be linear in binding free energy of Ig-antigen interaction. We expect that this simplification captures the key factor determining the AM. Such a coarse-grained description reduces the parameter space greatly, making it possible to search the whole parameter space for optimal design of GC. With this basic picture, we can build more detailed simulations to reproduce the complete procedures of AM.

Supporting Information

Figure S1 The scatter plot of affinity X and the change of affinity ΔX from PINT database, which does not show significant correlation.

References

1. MacLennan IC (1994) Germinal centers. Annu Rev Immunol 12: 117–139.
2. Rajewsky K (1996) Clonal selection and the antibody system. Nature 381: 731–736.
3. Allen CD, Okada T, Cyster JG (2007) Germinal-center organization and cellular dynamics. Immunity 27: 190–202.
4. Schwickert TA, Lindquist RL, Shakhar G, Livshits G, Skokos D, et al. (2007) In vivo imaging of germinal centres reveals a dynamic open structure. Nature 446: 83–87.
5. Neuberger MS (2002) Novartis Medal Lecture. Antibodies: a paradigm for the evolution of molecular recognition. Biochem Soc Trans 30: 341–350.
6. Kepler TB, Perelson AS (1993) Somatic hypermutation in B cells: an optimal control treatment. J Theor Biol 164: 37–64.
7. Oprea M, Perelson AS (1997) Somatic mutation leads to efficient affinity maturation when centrocytes recycle back to centroblasts. J Immunol 158: 5155–5162.
8. Kleinberg SH, Singh JP (2001) Toward quantitative simulation of germinal center dynamics: biological and modeling insights from experimental validation. J Theor Biol 211: 253–273.
9. Berek C, Milstein C (1987) Mutation drift and repertoire shift in the maturation of the immune response. Immunol Rev 96: 30–50.
10. Kepler TB, Perelson AS (1993) Somatic hypermutation in B cells: an optimal control treatment. J Theor Biol 164: 37–64.
11. Kleinberg SH, Singh JP (2001) Toward quantitative simulation of germinal center dynamics: biological and modeling insights from experimental validation. J Theor Biol 211: 253–273.
12. Sharon J (1990) Structural correlates of high antibody affinity: three engineered amino acid substitutions can increase the affinity of an anti-p-azophenylarsenate antibody 200-fold. Proc Natl Acad Sci U S A 87: 4814–4817.
13. Ulrich HD, Mundorff E, Santarsiero BD, Driggers EM, Stevens RC, et al. (1997) The interplay between binding energy and catalysis in the evolution of a catalytic antibody. Nature 389: 271–275.
14. Yang PL, Schultz PG (1999) Mutational analysis of the affinity maturation of antibody 48G7. J Mol Biol 294: 1191–1201.
15. Deem MW, Lee HY (2003) Sequence space localization in the immune system response to vaccination and disease. Phys Rev Lett 91: 068101.
16. Kroese FG, Wubbena AS, Seijen HG, Nieuwenhuijin P (1987) Germinal centers develop oligoclonally. Eur J Immunol 17: 1069–1072.
17. Coffey F, Alabeyev B, Maner T (2009) Initial clonal expansion of germinal center B cells takes place at the perimeter of follicles. Immunity 30: 599–609.
18. McHeyzer-Williams MG, McLean MJ, Lator NF, Nossal GJ (1993) Antigen-driven B cell differentiation in vivo. J Exp Med 178: 295–307.
19. Ha S, Zheng B, Dal Porto J, Kelloe G (1995) In situ studies of the primary immune response to (4-hydroxy-5-nitrophenylacetyl) IV. Affinity-dependent, antigen-driven B cell apoptosis in germinal centers as a mechanism for maintaining self-tolerance. J Exp Med 182: 1635–1641.
20. Jacob J, Przydupa J, Miller C, Kelloe G (1995) In situ studies of the primary immune response to (4-hydroxy-5-nitrophenylacetyl) III. The kinetics of V region mutation and selection in germinal center B cells. J Exp Med 178: 1293–1307.
21. Pascoal V, Lis VJ, Magalhães A, de Bouteiller O, Banchereau J, et al. (1994) Analysis of somatic mutation in five B cell subsets of human tonsil. J Exp Med 180: 329–339.
22. Allen CD, Okada T, Tang HL, Cyster JG (2007) Imaging of germinal center selection events during affinity maturation. Science 313: 520–523.
23. Hanna MG, Jr. (1964) An Autoradiographic Study of the Germinal Center in Human Tonsils. J Theor Biol 211: 253–275.
24. Allen CD, Okada T, Tang HL, Cyster JG (2007) Imaging of germinal center selection events during affinity maturation. Science 313: 520–523.
25. Hanna MG, Jr. (1964) An Autoradiographic Study of the Germinal Center in Human Tonsils. J Theor Biol 211: 253–275.

Acknowledgments

We are grateful to S. Wylie for helpful discussions, and A. Perelson for drawing our attention to the improvement of affinity.

Author Contributions

Conceived and designed the experiments: EIS. Performed the experiments: JZ EIS. Analyzed the data: JZ EIS. Wrote the paper: JZ EIS.
24. Zhang J, MacLennan IC, Liu YJ, Lane PJ (1988) Is rapid proliferation in B centroblasts linked to somatic mutation in memory B cell clones? Immunol Lett 18: 297–299.
25. Shannon M, Mehr R (1999) Reconciling repertoire shift with affinity maturation: the role of deleterious mutations. J Immunol 162: 3950–3956.
26. Shlomchik MJ, Watts P, Weigert MG, Litwin S (1998) Clone: a Monte-Carlo computer simulation of B cell clonal expansion, somatic mutation, and antigen-driven selection. Curr Top Microbiol Immunol 229: 173–197.
27. Kumar MD, Gromiha MM (2006) PINT: Protein-protein Interactions Thermodynamic Database. Nucleic Acids Res 34: D195–198.
28. Kocks C, Rajewsky K (1988) Stepwise intralacnal maturation of antibody affinity through somatic hypermutation. Proc Natl Acad Sci U S A 85: 8206–8210.
29. Battista FD, Neuberger MS (1998) Affinity dependence of the B cell response to antigen: a threshold, a ceiling, and the importance of off-rate. Immunity 8: 751–759.
30. Tsimring LS, Levine H, Kessler DA (1996) RNA virus evolution via a fitness-space model. Phys Rev Lett 76: 4440–4444.
31. Kuppers R, Zhao M, Hansmann ML, Rajewsky K (1993) Tracing B cell development in human germinal centers by molecular analysis of single cells picked from histological sections. Embo J 12: 4955–4967.
32. Desai MM, Fisher DS (2007) Beneficial mutation selection balance and the effect of linkage on positive selection. Genetics 176: 1759–1798.
33. Rouzine IM, Brunet E, Wilke CO (2008) The traveling-wave approach to asexual evolution: Müller’s ratchet and speed of adaptation. Theor Popul Biol 73: 24–46.
34. Brunet E, Rouzine IM, Wilke CO (2008) The stochastic edge in adaptive evolution. Genetics 179: 603–620.
35. Rouzine IM, Wakeley J, Collin JM (2003) The solitary wave of asexual evolution. Proc Natl Acad Sci U S A 100: 587–592.
36. Liu YJ, Zhang J, Lane PJ, Chan EY, MacLennan IC (1991) Sites of specific B cell activation in primary and secondary responses to T cell-dependent and T cell-independent antigens. Eur J Immunol 21: 2951–2962.
37. Jacob J, Kassir R, Kelsoe G (1992) In situ studies of the primary immune response to (4-hydroxy-3-nitrophenyl)acetyl. I. A common clonal origin for periarteriolar lymphoid sheath-associated foci and germinal centers, J Exp Med 176: 679–687.
38. Iber D, Maini PK (2002) A mathematical model for germinal centre kinetics and affinity maturation. J Theor Biol 219: 153–175.
39. Kemeny C, De Boer RJ (1999) A mathematical model on germinal center kinetics and termination. J Immunol 163: 2463–2469.
40. Meyer-Hermann M, Deutsch A, Or-Guil M (2001) Recycling probability and dynamical properties of germinal center reactions. J Theor Biol 210: 263–285.
41. Wedemayer GJ, Patten PA, Wang LH, Schulz PG, Stevens RC (1997) Structural insights into the evolution of an antibody combining site. Science 276: 1665–1669.
42. Berek C, Berger A, Apel M (1994) Maturation of the immune response in germinal centers. Cell 75: 1121–1129.
43. Sharon J, Gefter ML, Wysocki LJ, Margolies MN (1989) Recurrent somatic mutations in mouse antibodies to p-azophenylarsenate increase affinity for hapten. J Immunol 142: 596–601.
44. Serkevitz M, Kocks C, Rajewsky K, Daldrop R (1987) Analysis of somatic muta
tion and class switching in naive and memory B cells generating adoptive primary and secondary responses. Cell 48: 757–770.
45. O’Connor BP, Vogel LA, Zhang W, Loo W, Shnider D, et al. (2006) Imprinting antigen recognition strength regulates the choice between extrafollicular plasma cell and germinal center B cell differentiation. J Exp Med 203: 1081–1091.
46. Ziegler M, Steinhauser G, Berek C (1994) Development of antibody diversity in single germinal centers: selective expansion of high-affinity variants. Eur J Immunol 177: 7273–7312.
47. Paus D, Phan TG, Chan TD, Gardam S, Bastaen A, et al. (2006) Antigen recognition strength regulates the choice between extrac
follicular plasma cell and germinal center B cell differentiation. J Exp Med 203: 1081–1091.
48. Ziegler M, Steinhauser G, Berek C (1994) Development of antibody diversity in single germinal centers: selective expansion of high-affinity variants. Eur J Immunol 24: 2393–2400.
49. Radmacher MD, Kehoe G, Kepler TB (1998) Predicted and inferred waiting times for key mutations in the germinal centre reaction: evidence for stochasticity in selection. Immunol Cell Biol 76: 373–381.
50. Meyer-Hermann ME, Maini PK, Iber D (2006) An analysis of B cell selection mechanisms in germinal centers. Math Med Biol 23: 253–277.
51. Kesmir C, De Boer RJ (1999) A mathematical model on germinal center kinetics and termination. J Immunol 163: 2463–2469.
52. Radmacher MD, Kelsoe G, Kepler TB (1998) Predicted and inferred waiting times for key mutations in the germinal centre reaction: evidence for stochasticity in selection. Immunol Cell Biol 23: 253–277.
53. Ziegler M, Steinhauser G, Berek C (1994) Development of antibody diversity in single germinal centers: selective expansion of high-affinity variants. Eur J Immunol 177: 7273–7312.
54. Shahaf G, Barak M, Zuckerbaum NS, Swerdlff N, Gorfine M, et al. (2008) Antigen-driven selection in germinal centers as reflected by the shape characteristics of immunglobulin gene lineage trees: a large-scale simulation study. J Theor Biol 253: 210–222.
55. Jacob J, Kehoe G (1992) In situ studies of the primary immune response to (4-hydroxy-3-nitrophenylacetyl). II. A common clonal origin for periarteriolar lymphoid sheath-associated foci and germinal centers. J Exp Med 176: 679–687.
56. Iber D, Maini PK (2002) A mathematical model for germinal centre kinetics and affinity maturation. J Theor Biol 219: 153–175.
57. Kemeny C, De Boer RJ (1999) A mathematical model on germinal center kinetics and termination. J Immunol 163: 2463–2469.